Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 4/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | PRMT5 | O14744 | 6/20 | 0.66 |
| ▸ | EGFR | P00533 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | RAD52 | P43351 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | OXTR | P30559 | 1/20 | 0.60 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | DRD2 | P14416 | 2/20 | 0.58 |
| ▸ | HTR2A | P28223 | 2/20 | 0.57 |
| ▸ | HTR2C | P28335 | 2/20 | 0.57 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HTR2B | P41595 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6782129 | 0.88 | HTR7 (0.82) | HTR7CYP3A4CYP2D6CYP2C19PRMT5 | |
| SCHEMBL764888 | 0.87 | HTR2B (0.72) | HTR7MAPTDRD2HTR2AHTR2C | |
| SCHEMBL8325204 | 0.86 | HTR7 (0.67) | HTR7CYP3A4CYP2D6CYP2C19PRMT5 | |
| SCHEMBL23875876 | 0.86 | HTR7 (0.67) | HTR7CYP3A4CYP2D6CYP2C19PRMT5 | |
| SCHEMBL23876089 | 0.86 | HTR7 (0.67) | HTR7CYP3A4CYP2D6CYP2C19PRMT5 | |
| SCHEMBL3709723 | 0.85 | HTR7 (0.78) | HTR7CYP3A4CYP2D6CYP2C19PRMT5 | |
| SCHEMBL765058 | 0.85 | HTR7 (0.72) | HTR7CYP3A4CYP2D6CYP2C19KMT2A | |
| SCHEMBL763727 | 0.85 | HTR7 (0.72) | HTR7CYP3A4CYP2D6CYP2C19PRMT5 | |
| SCHEMBL274149 | 0.84 | HTR7 (1.00) | HTR7CYP3A4CYP2D6CYP2C19PRMT5 | |
| SCHEMBL7488979 | 0.84 | HTR7 (0.67) | HTR7CYP3A4CYP2D6CYP2C19PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115850269-A | Tetrahydro-beta-carboline compound and preparation method and application thereof | 南京工业大学 | 2023-03-28 | — | — | CN | disclosed |
| US-20220202786-A1 | METHODS FOR TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2022-06-30 | — | — | US | disclosed |
| US-20220202786-A1 | METHODS FOR TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2022-06-30 | — | — | US | disclosed |
| US-11202775-B2 | Methods for treatment of cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2021-12-21 | — | — | US | disclosed |
| US-11202775-B2 | Methods for treatment of cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2021-12-21 | — | — | US | disclosed |
| WO-2021195603-A1 | ANTI-MALARIAL COMPOUNDS AND USES THEREOF | VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY (US) | 2021-09-30 | — | — | WO | disclosed |
| CN-108218864-B | A kind of green synthesis method of tetrahydro-beta-carboline heterocyclic compound | 温州大学 | 2019-08-27 | — | — | CN | disclosed |
| CN-108218864-A | A kind of green synthesis method of tetrahydro-beta-carboline heterocyclic compound | 温州大学 | 2018-06-29 | — | — | CN | disclosed |
| EP-2214485-B1 | METHODS FOR TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORP (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-2214485-B1 | METHODS FOR TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORP (US) | 2016-07-20 | — | — | EP | disclosed |
| US-20080064683-A1 | Inhibition of VEGF Translation | PTC THERAPEUTICS, INC. | 2008-03-13 | — | — | US | disclosed |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | PCT THERAPEUTICS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | PCT THERAPEUTICS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070254878-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. | 2007-11-01 | — | — | US | disclosed |
| US-20070254878-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. | 2007-11-01 | — | — | US | disclosed |
| WO-2005089764-A9 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS INC (US) | 2007-09-13 | — | — | WO | disclosed |
| EP-0912567-B1 | CARBOLINE DERIVATIVES | ICOS CORP (US) | 2002-04-10 | — | — | EP | disclosed |
| US-6306870-B1 | PHOSPHODIESTERASE ENZYME INHIBITORS, CARDIOVASCULAR DISORDERS AND SEXUAL DISORDERS | ICOS CORPORATION | 2001-10-23 | — | — | US | disclosed |
| US-6117881-A | POTENT AND SELECTIVE INHIBITORS OF CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE SPECIFIC PHOSPHODIESTERASE | ICOS CORPORATION (US) | 2000-09-12 | — | — | US | disclosed |
| US-6043252-A | A POTENT AND SELECTIVE INHIBITORS OF CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE SPECIFIC PHOSPHODIESTERASE (CGMP-SPECIFIC PDE); TREATING CARDIOVASCULAR DISORDERS AND ERECTILE DYSFUNCTION | ICOS CORPORATION (US) | 2000-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11202775-B2 | Methods for treatment of cancer | TP53, TOP2B, BRCA1 | HTR7 3317/4885CYP3A4 860/4885CYP2D6 1833/4885 |
| US-20080064683-A1 | Inhibition of VEGF Translation | EIF4E, EIF4EBP1, VEGFA | HTR7 3313/4885CYP3A4 4618/4885CYP2D6 4417/4885 |
| US-20070254878-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | VEGFA, FLT4, FLT1 | HTR7 1737/4885CYP3A4 2064/4885CYP2D6 4041/4885 |
| US-20220202786-A1 | METHODS FOR TREATMENT OF CANCER | TP53, TOP2B, BRCA1 | HTR7 3317/4885CYP3A4 860/4885CYP2D6 1833/4885 |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | VEGFA, FLT4, MIF | HTR7 1021/4885CYP3A4 3539/4885CYP2D6 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.